Topical Crisaborole in the Treatment of Atopic Hand Dermatitis: A Retrospective Chart Review

Kahn, Jared S.; Grossman-Kranseler, Julie; Zancanaro, Pedro; Griffiths, Delaney; Dumont, Nicole; Rosmarin, David

doi:10.1097/der.0000000000000793

Cited by 4 publications

(3 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has proved its efficacy in atopic dermatitis both in adults and children. Additionally, a retrospective review involving 251 patients indicates that it could be a successful therapy for CHE, with 72.2% of individuals experiencing an amelioration in their symptoms [ 51 ].…”

Section: Resultsmentioning

confidence: 99%

New Perspectives in the Management of Chronic Hand Eczema: Lessons from Pathogenesis

Tancredi,

Buononato,

Caccavale

et al. 2023

IJMS

View full text Add to dashboard Cite

Chronic hand eczema (CHE) is a common inflammatory skin condition that significantly impacts the quality of life. From work-related disabilities to social embarrassment, pain, and financial costs, the burden on society is substantial. Managing this condition presents challenges such as long-term treatment, poor patient compliance, therapy side effects, and economic feasibility. As a result, significant efforts have been made in this field in recent years. Specifically, the broader understanding of CHE pathogenesis has led to the development of new drugs, both topical and systemic. The aim of this narrative review is to summarize the current available data on hand eczema pathophysiology and explore the resulting developments in drugs for its treatment. A comprehensive search on PubMed and the other main scientific databases was conducted using keywords related to CHE and its pathogenesis. The most relevant pathways targeted by therapies include the JAK-STAT cascade, IL-4, and IL-13 axis, phosphodiesterase 4 enzyme, and chemo-attractant cytokines. In the near future, physicians will have a plethora of therapeutic alternatives. Consequently, they should be well-trained not only in how to use these alternatives but also how to combine these treatments to address the ongoing challenges related to efficacy, tolerability, and safety.

show abstract

Section: Resultsmentioning

confidence: 99%

New Perspectives in the Management of Chronic Hand Eczema: Lessons from Pathogenesis

Tancredi,

Buononato,

Caccavale

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…31 A retrospective chart review of 251 patients further suggests that it may be an effective treatment for hand AD with 72.2% of patients having an improvement of symptoms, 38.9% being "clear" and 61.1% being "clear" or "almost clear". 32 Physical therapies such as UV(ultraviolet light) phototherapy have also previously been used to treat hand eczema second-line to topical treatments in clinical practice. 33 Local psoralen plus UVA therapy (PUVA) has been reported to improve investigator-rated control of hand eczema compared to narrow-band UVB therapy in hand eczema.…”

Section: Molecular Pathways Of Hand Eczemamentioning

confidence: 99%

Section: Pathogenesis Of Hand Eczemamentioning

confidence: 99%

A Review of Existing and New Treatments for the Management of Hand Eczema

Molin

2023

J Cutan Med Surg

View full text Add to dashboard Cite

Hand eczema is a chronic condition that affects an estimated 14.5% of the general population. It has severe quality of life ramifications in those that struggle with it, including days missed from work or school, productivity loss and impaired work functioning. For years, the standard of care included topical moisturizing creams, topical steroids and more recently systemic agents. As new therapeutic targets emerge and recent advances are being developed, it is now more possible than ever that hand eczema can be managed via the underlying mechanisms. A review of the literature was conducted to identify current treatment options for hand eczema and chronic hand eczema. The terms ‘hand eczema’, ‘hand dermatitis’ were used to search PubMed, CENTRAL and Embase. To identify new therapies still undergoing investigation, we used the terms ‘hand eczema’, ‘hand dermatitis’, ‘atopic dermatitis’, and ‘vesicular eczema of hands and/or feet’ to search Clinicaltrials.gov for all studies until December 2022. There were 56 ongoing clinical trials identified for pharmacological treatments for hand eczema on Clinicaltrials.gov from 2000 - 2022, with 16 that are new or ongoing. These included studies for dupilumab, ruxolitinib, delgocitinib (LEO124249), gusacitinib (ASN002), AFX 5931, and roflumilast (ARQ-252). Two major classes of drugs emerging for the treatment of hand eczema include IL-4/IL-13 inhibitors and JAK inhibitors. With the increase in efficacy seen with these new drugs, we are also noting improved adverse effect profiles, making them attractive options to add to a clinician’s management toolbox for patients with hand eczema.

show abstract

Management of Atopic Hand Dermatitis

Port,

Brunner

2024

Dermatologic Clinics

View full text Add to dashboard Cite

Topical Crisaborole in the Treatment of Atopic Hand Dermatitis: A Retrospective Chart Review

Cited by 4 publications

References 4 publications

New Perspectives in the Management of Chronic Hand Eczema: Lessons from Pathogenesis

New Perspectives in the Management of Chronic Hand Eczema: Lessons from Pathogenesis

A Review of Existing and New Treatments for the Management of Hand Eczema

Management of Atopic Hand Dermatitis

Contact Info

Product

Resources

About